Multidrug- and extensively drug-resistant tuberculosis, Germany

Area of Science:

• Medicine
• Infectious Diseases
• Public Health

Background:

• Tuberculosis (TB) remains a global health challenge, with increasing concern over multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains.
• Understanding the epidemiology and treatment outcomes of MDR/XDR-TB is crucial for effective control strategies.

Purpose of the Study:

• To evaluate risk factors and treatment outcomes for multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) in Germany.
• To identify patient demographics and resistance patterns associated with MDR and XDR-TB.
• To assess the effectiveness of available treatment regimens, including linezolid, for MDR/XDR-TB.

Main Methods:

• Retrospective analysis of culture-positive TB cases in Germany from 2004-2006.
• Identification and characterization of Mycobacterium tuberculosis isolates for drug resistance patterns (MDR and XDR).
• Evaluation of patient demographics, hospitalization duration, and treatment success rates.

Main Results:

• MDR-TB was identified in 4% and XDR-TB in 0.15% of TB cases.
• A significant proportion (80%) of patients with MDR/XDR-TB were born in former Soviet Union countries.
• Patients with XDR-TB experienced longer hospitalizations and higher rates of resistance to first-line drugs compared to MDR-TB patients.
• Treatment success rates were 59% for the entire cohort and 87% for those with a definitive outcome.
• Linezolid was used in 40% of treated patients.

Conclusions:

• MDR and XDR-TB in Germany are primarily associated with immigration from specific regions.
• Extensive drug susceptibility testing and comprehensive inpatient management contribute to favorable treatment outcomes.
• Continued surveillance and access to second- and third-line drugs are essential for managing drug-resistant TB.